Prostate Cancer - Feb 23, 2018 Edition

Health News and Information - News Medical

February 23, 2018     Prostate Cancer     The latest prostate cancer news from News Medical

Study of men with inherited DNA repair mutations opens new therapeutic avenues in prostate cancer   Selected by the American Society of Clinical Oncology (ASCO) to first outing during its Genitourinary Cancers Symposium, Translating Evidence to Multidisciplinary Care, February 8 - 10 (San Francisco, USA)

Myriad’s myRisk Hereditary Cancer test finds inherited gene mutations in more than 12% of prostate cancer patients   Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162 patient study of the Myriad myRisk Hereditary Cancer test will be featured during the poster presentation at the 2018 Genitourinary Cancer Symposium in San Francisco, Calif.         New genetic risk score could help guide screening decisions for prostate cancer   One of the biggest challenges in treating prostate cancer is distinguishing men who have aggressive and potentially lethal disease from men whose cancer is slow-growing and unlikely to metastasize.

Scientists develop fluorescent probe to identify cancer stem cells   Cells with stem-cell characteristics appear to be especially important in the formation and metastasis of tumors. Scientists have now developed a universal fluorescent probe for these “cancer stem cells”. As reported in the journal Angewandte Chemie, this dye also selectively kills off the cells.       Black patients found to be underrepresented in prostate cancer clinical trials   Clinical trials can offer patients access to cutting-edge treatments with the potential to extend their survival and shape the standard of care in the future.       German researchers find way to accurately differentiate prostate cancer from benign tissue   Using nuclear medicine, German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in the February issue of The Journal of Nuclear Medicine.       FDA approves new treatment for non-metastatic, castration-resistant prostate cancer   The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.

Website: www.news-medical.net Email: info@news-medical.net Telephone: +44 (0)161 457 7150 AZoNetwork UK Ltd. NEO, 4th Floor 9 Charlotte Street, Manchester M1 4ET, UK